Temasek
Singapore sovereign wealth fund; ~$290bn portfolio; Tropic Biosciences investor.
Last refreshed: 13 April 2026
Why is Singapores sovereign fund backing a British gene-editing crop startup?
Timeline for Temasek
Mentioned in: Tropic Biosciences raises $105m from Norwich
UK Startups and Innovation- What does Temasek invest in?
- Temasek invests across technology, financials, life sciences, real assets, and consumer sectors. It has been increasing allocations to food security and synthetic biology.Source: uk-startups-and-innovation
- Why is Temasek interested in agricultural biotech?
- Singapore imports most of its food, making food security a national strategic priority. Temasek backs agri-biotech ventures as part of a mandate to support long-term food system resilience.Source: uk-startups-and-innovation
- Is Temasek the same as GIC?
- No. Temasek and GIC are separate Singapore sovereign funds. Temasek focuses on direct company investments; GIC manages foreign reserves in a broader portfolio including bonds and equities.Source: uk-startups-and-innovation
Background
Temasek is Singapores sovereign wealth fund and one of the investors backing Tropic Biosciences, the Norwich-based gene-editing agriculture startup that raised $105m in its Series B. The investment illustrates Temaseks growing appetite for synthetic biology and food security assets, a strategic priority driven by Singapores dependence on food imports and its long-term position as a hub for Asian agricultural technology.
Established in 1974 and wholly owned by the Singapore government, Temasek manages a portfolio of approximately S$389bn (around $290bn USD) across technology, financials, life sciences, consumer, and real assets. Unlike many sovereign wealth funds, Temasek operates as an active investor, often taking board representation and engaging with management strategy rather than simply holding passive stakes. It has backed companies including Alibaba, DBS Group, and Singapore Airlines.
Temaseks presence in a UK agri-biotech round is consistent with its stated mandate to invest in the long-term wellbeing of Singapore, which the fund interprets broadly to include global food system resilience. For Tropic Biosciences, the backing of a sovereign investor with deep Asian market relationships is strategically valuable: banana disease resistance and crop trait editing have the largest potential markets in Southeast Asia, Africa, and Latin America, precisely the regions Temasek is best positioned to help navigate.